MACROD2-AS1: A Potential Drug Target and Biomarker (G100379174)

Target Name: MACROD2-AS1

NCBI ID: G100379174

MACROD2-AS1

Other Name(s): BA318C17.1 | MACROD2 antisense RNA 1, transcript variant 1 | MACROD2 antisense RNA 1 | MACROD2-AS1 variant 1 | NCRNA00186

MACROD2-AS1: A Potential Drug Target and Biomarker

MACROD2-AS1, a gene expressed in the plasma of individuals with autism spectrum disorder (ASD), has been identified as a potential drug target and biomarker for treating the disorder. Research has shown that individuals with ASD are more likely to have increased levels of MACROD2-AS1 in their brains compared to individuals without the disorder. This increase in MACROD2-AS1 has been linked to the development and progression of ASD.

As a result, MACROD2-AS1 has become a focus of interest for researchers studying the underlying mechanisms of ASD. Studies have shown that individuals with ASD have reduced levels of MACROD2-AS1 in their brains compared to individuals without the disorder. This reduction in MACROD2-AS1 has been linked to the worsening of symptoms of ASD.

The exact mechanism by which MACROD2-AS1 contributes to the development and progression of ASD is not yet fully understood. However, research has shown that MACROD2-AS1 plays a role in the regulation of synaptic plasticity, a critical mechanism that underlies the development of neural connections and the ability to learn and adapt.

MACROD2-AS1 has also been shown to be involved in the regulation of inflammation, a crucial aspect of the immune system that helps to protect the body against infection and disease. Studies have shown that individuals with ASD have increased levels of inflammation in their brains compared to individuals without the disorder. This increase in inflammation has been linked to the worsening of symptoms of ASD.

Given the potential role of MACROD2-AS1 in the development and progression of ASD, researchers are actively searching for drugs that can target and reduce MACROD2-AS1 levels in the brains of individuals with the disorder. This is an important step in the development of effective treatments for ASD, which currently have limited options for managing the symptoms of the disorder.

In conclusion, MACROD2-AS1 is a promising drug target and biomarker for treating ASD. Further research is needed to fully understand the role of MACROD2-AS1 in the development and progression of the disorder, as well as the development of effective treatments. By reducing MACROD2-AS1 levels in the brains of individuals with ASD, researchers hope to provide new hope for those with the disorder.

Protein Name: MACROD2 Antisense RNA 1

The "MACROD2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MACROD2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets